Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines

Phase 3 Completed 105 enrolled Ottawa Hospital Research Institute Hamilton Health Sciences Corporation · collab Queen Elizabeth II Health Sciences Centre · collab University of Alberta · collab

RandomizedParallel-groupOpen-labelPrevention

Summary

Purpose of the Pilot Trial: To determine the feasibility of conducting a multicentre randomized open label controlled trial evaluating the use of prophylactic dose rivaroxaban to prevent central venous catheter (CVC) associated venous thromboembolism (VTE) among cancer patients. Hypothesis: treatment with low dose rivaroxaban (10mg) will reduce the incidence of upper extremity venous thrombosis in a high risk population with cancer and CVC.

Timeline

Start: 2019-03-15
Primary completion: 2020-05-14
Completion: 2020-06-14

Publications

Results Ikesaka R, Siegal D, Mallick R, Wang TF, Witham D, Webb C, Carrier M; Canadian Venous Thromboembolism Research Network (CanVECTOR). Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): A two-center open-label pilot randomized controlled trial. Res Pract Thromb Haemost. 2021 May 5;5(4):e12517. doi: 10.1002/rth2.12517. eCollection 2021 May.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivaroxaban	Other / unclassified	10 mg	Oral

Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines

Summary

Timeline

Publications

Drugs

Indications